Article
Medicine, General & Internal
A. Bardia, S. A. Hurvitz, S. M. Tolaney, D. Loirat, K. Punie, M. Oliveira, A. Brufsky, S. D. Sardesai, K. Kalinsky, A. B. Zelnak, R. Weaver, T. Traina, F. Dalenc, P. Aftimos, F. Lynce, S. Diab, J. Cortes, J. O'Shaughnessy, V Dieras, C. Ferrario, P. Schmid, L. A. Carey, L. Gianni, M. J. Piccart, S. Loibl, D. M. Goldenberg, Q. Hong, M. S. Olivo, L. M. Itri, H. S. Rugo
Summary: Patients with metastatic triple-negative breast cancer treated with Sacituzumab govitecan had significantly longer progression-free and overall survival compared to standard chemotherapy, but experienced more frequent myelosuppression and diarrhea as adverse events.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, Research & Experimental
Jing Li, Xiaoqin Xu, Xiting Peng
Summary: This study investigated the mechanism of cisplatin resistance in triple-negative breast cancer (TNBC). The results revealed that NDC80 was a cisplatin-resistant gene and its expression differed between cisplatin-sensitive and resistant cells. NDC80 was found to be overexpressed in TNBC tissues and increased after cisplatin treatment. Moreover, NDC80 overexpression promoted the viability and proliferation of TNBC cells and enhanced their resistance to cisplatin. The study also identified potential pathways associated with cisplatin resistance.
ARCHIVES OF MEDICAL RESEARCH
(2022)
Article
Oncology
Juan Luis Gomez Marti, Colin H. Beckwitt, Amanda M. Clark, Alan Wells
Summary: The study examined the effects of atorvastatin on chemotherapy for mTNBC through animal models and clinical correlations. Atorvastatin was found to have additive effects with doxorubicin targeting liver metastases, and the combination of atorvastatin and chemotherapy led to increased cell death in dormant cancer cells.
BRITISH JOURNAL OF CANCER
(2021)
Article
Oncology
Yuan Yuan, Susan E. Yost, Yujie Cui, Christopher Ruel, Mireya Murga, Aileen Tang, Norma Martinez, Daniel Schmolze, James Waisman, Niki Patel, Lalit Vora, Lusine Tumyan, Mari Bozoghlanian, Daphne Stewart, Paul H. Frankel
Summary: This trial evaluated the safety and efficacy of ipatasertib in combination with different chemotherapy regimens for metastatic triple-negative breast cancer (mTNBC). The results showed that continuous dosing of ipatasertib with chemotherapy was safe and well-tolerated, and the overall response rates and progression-free survival varied among the different treatment arms. Further study is needed to better understand the role of AKT inhibition in the treatment of TNBCs.
Article
Oncology
Yuan Yuan, Susan E. Yost, Yujie Cui, Christopher Ruel, Mireya Murga, Aileen Tang, Norma Martinez, Daniel Schmolze, James Waisman, Niki Patel, Lalit Vora, Lusine Tumyan, Mari Bozoghlanian, Daphne Stewart, Paul H. Frankel
Summary: This study evaluated the safety and efficacy of ipatasertib in combination with carboplatin, carboplatin/paclitaxel, or capecitabine/atezolizumab in patients with metastatic triple-negative breast cancer (mTNBC). The primary endpoints were safety and recommended phase II dose (RP2D), while secondary endpoints included progression-free survival (PFS), response rate, and overall survival. The results showed that continuous dosing of ipatasertib with chemotherapy was safe and well-tolerated, and further research is needed to understand the role of AKT inhibition in the treatment of TNBC.
Article
Oncology
Karama Asleh, Ana Lluch, Angela Goytain, Carlos Barrios, Xue Q. Wang, Laura Torrecillas, Dongxia Gao, Manuel Ruiz-Borrego, Samuel Leung, Jose Bines, Angel Guerrero-Zotano, Jose Angel Garcia-Saenz, Juan Miguel Cejalvo, Jesus Herranz, Roberto Torres, Juan de la Haba-rodriguez, Francisco Ayala, Henry Gomez, Federico Rojo, Torsten O. Nielsen, Miguel Martin
Summary: This study aimed to validate the predictive biomarkers for capecitabine benefit in triple-negative breast cancer (TNBC). The results showed that the non-basal subtype was the most significant predictor, identifying patients who were most likely to benefit from capecitabine treatment.
CLINICAL CANCER RESEARCH
(2023)
Article
Pharmacology & Pharmacy
Selase Ativui, Cynthia A. Danquah, Paul Poku Sampene Ossei, Michael Ofori
Summary: This study demonstrated that palmatine has the potential to improve hypoxemia, ameliorate metastasis-associated lung injury, decrease lung MTA1 expression, and increase p53 expression in the treatment of lung metastasis from triple negative breast cancer.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Oncology
Jie Bai, Xufeng Yao, Yinghong Pu, Xiaoyi Wang, Xinrong Luo
Summary: This meta-analysis suggests that adjuvant capecitabine-based chemotherapy can improve disease-free survival and overall survival in early-stage triple-negative breast cancer patients. Patients with lymph node negative status and those who receive capecitabine for six cycles or more may benefit the most.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Xueqiong Xun, Qinguang Cao, Pan Hong, Saroj Rai, Yeming Zhou, Ruikang Liu, Huiyong Hu
Summary: This meta-analysis found that the addition of capecitabine to standard adjuvant chemotherapy in early-stage TNBC patients significantly improved disease-free survival and overall survival with manageable adverse events. Lower dosage and higher frequency of capecitabine combined with adjuvant chemotherapy showed better survival outcomes.
FRONTIERS IN ONCOLOGY
(2022)
Review
Chemistry, Inorganic & Nuclear
Nafees Muhammad, Muhammad Hanif, Piaoping Yang
Summary: Triple-negative breast cancer is an aggressive and hard-to-treat form of breast cancer, which poses an urgent medical need. The lack of receptors makes it challenging to develop more effective targeted therapies. Therefore, the investigation and development of innovative multimodal strategies are needed to target this specific type of breast cancer.
COORDINATION CHEMISTRY REVIEWS
(2024)
Review
Pharmacology & Pharmacy
Xueqiong Xun, Jun Ai, Fuhui Feng, Pan Hong, Saroj Rai, Ruikang Liu, Baowen Zhang, Yeming Zhou, Huiyong Hu
Summary: This meta-analysis found that the use of Bevacizumab in patients with triple-negative breast cancer and HER-2 negative metastatic breast cancer may increase the incidence of serious adverse events, indicating a need for caution in its usage.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Pharmacology & Pharmacy
Omkar Bhatavdekar, Ines Godet, Daniele Gilkes, Stavroula Sofou
Summary: Understanding the effects of chemotherapy delivery on different hypoxic cell sub-populations is important for controlling tumor growth and metastasis in triple negative breast cancer. In this study, multicellular spheroids were used to evaluate the effects of cisplatin exposure rate and pattern on cell viability and motility. It was found that cell resistance to cisplatin increased with exposure to hypoxia, but not acidosis. Increasing the exposure rate of cisplatin in spheroids enhanced chemotherapy sensitivity and reduced metastatic potential, even in hypoxic cells. This effect was achieved using nanocarriers that quickly released cisplatin and deeply penetrated the spheroid interstitium.
Letter
Medicine, General & Internal
Ryan Sun, Lee-Jen Wei
Summary: This article discusses the clinical benefits of pembrolizumab combined with chemotherapy in patients with triple-negative breast cancer. The authors suggest that both hazard values and ratios should be considered when evaluating clinical benefits.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Brie Chun, Joanna Pucilowska, ShuChing Chang, Isaac Kim, Benjamin Nikitin, Yoshinobu Koguchi, William L. Redmond, Brady Bernard, Venkatesh Rajamanickam, Nathan Polaske, Paul A. Fields, Valerie Conrad, Mark Schmidt, Walter J. Urba, Alison K. Conlin, Heather L. McArthur, David B. Page
Summary: This study investigates the effects of pembrolizumab combined with paclitaxel or capecitabine on T-cell subsets in triple-negative breast cancer patients. The results show that these treatments result in similar lymphodepletions across peripheral T-cell subsets and do not alter T-cell clonal diversity. The findings contribute to our understanding of the impact of chemoimmunotherapy on the immune system.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Oncology
Arielle L. Heeke, Antoinette R. Tan
Summary: Immunotherapy has become a key component in the treatment of cancer, with promising activity observed in metastatic triple-negative breast cancer (TNBC) through PD-1/PD-L1 checkpoint inhibitor therapy. Accelerated approvals by the FDA for atezolizumab and pembrolizumab in 2019 and 2020, respectively, have provided hope for the treatment of PD-L1-positive TNBC.
CANCER AND METASTASIS REVIEWS
(2021)
Article
Oncology
Yiqun Li, Qiao Li, Hongnan Mo, Xiuwen Guan, Shaoyan Lin, Zijing Wang, Yimeng Chen, Ye Zhang, Dainan Zhang, Shanshan Chen, Ruigang Cai, Jiayu Wang, Yang Luo, Ying Fan, Peng Yuan, Pin Zhang, Qing Li, Fei Ma, Binghe Xu
Summary: The study examined the incidence, risk factors, and survival of brain metastases at the initial diagnosis of metastatic breast cancer in China, revealing that patients with HER2-positive and TNBC subtypes have a higher risk of developing brain metastases at the initial diagnosis of MBC.
Article
Oncology
Hui Li, Jinsong Wang, Zongbi Yi, Chunxiao Li, Haijuan Wang, Jingyao Zhang, Ting Wang, Peng Nan, Feng Lin, Dongkui Xu, Haili Qian, Fei Ma
Summary: CDK12, co-amplified with HER2, can sensitize or resensitize HER2-positive breast cancer to anti-HER2 TKIs and suppress PI3K/AKT signaling. Patients with CDK12 amplification respond less sensitively to anti-HER2 treatment compared to those without, leading to a significantly shortened progression-free survival.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Xiuwen Guan, Chunxiao Li, Yiqun Li, Jiani Wang, Zongbi Yi, Binliang Liu, Hongyan Chen, Jiasen Xu, Haili Qian, Binghe Xu, Fei Ma
Summary: This study found that the presence of EMT-like CTC-WBC clusters in metastatic breast cancer patients undergoing specific treatment was associated with poorer progression-free survival, suggesting it could be used as a parameter to predict clinical outcomes and guide personalized therapy.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Yuanyuan Zhang, Hongyan Chen, Hongnan Mo, Xueda Hu, Ranran Gao, Yahui Zhao, Baolin Liu, Lijuan Niu, Xiaoying Sun, Xiao Yu, Yong Wang, Qing Chang, Tongyang Gong, Xiuwen Guan, Ting Hu, Tianyi Qian, Binghe Xu, Fei Ma, Zemin Zhang, Zhihua Liu
Summary: The study indicates that high levels of baseline CXCL13(+) T cells are associated with effective responses to combination therapy in triple-negative breast cancer patients. These cells increase following combination therapy but decrease after monotherapy, highlighting their importance in predicting treatment outcomes.
Article
Oncology
Yiqun Han, Jiayu Wang, Yanxia Sun, Pei Yu, Peng Yuan, Fei Ma, Ying Fan, Yang Luo, Pin Zhang, Qing Li, Ruigang Cai, Shanshan Chen, Qiao Li, Binghe Xu
Summary: This study aimed to conduct a retrospective analysis and establish a clinical prediction model to predict individual survival outcomes of patients with small breast carcinomas. A total of 17,543 patients diagnosed between 2013 and 2016 were analyzed to construct nomograms and predict 3-year, 5-year, and 10-year survival rates. The prognostic model provided a reasonable and effective method to predict the prognosis of patients with small breast cancer, identifying histologic grade, lymph node stage, hormone receptor status, and molecular subtypes as significant risk factors.
CLINICAL BREAST CANCER
(2021)
Article
Oncology
Bo Lan, Dan Lv, Xiaoying Sun, Min Yang, Li Zhang, Fei Ma
Summary: This study found that variations in IL-10, IFNGR1, and BDNF genes are associated with anxiety and depression symptoms in Chinese breast cancer patients. This can help identify patients at high risk for psychological problems during chemotherapy and improve personalized management and treatment.
CLINICAL BREAST CANCER
(2022)
Article
Otorhinolaryngology
Di Zhang, Lixi Li, Tingyu Wen, Fei Ma
Summary: This study aimed to explore the clinical characteristics, prognostic factors, and value of adjuvant therapy for major salivary duct carcinoma (SDC). The study found that age, tumor size, and lymph node involvement were independent prognostic factors, and adjuvant radiotherapy could improve survival rates for patients with tumors larger than 4 cm.
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
(2023)
Article
Oncology
Dan Lv, Bo Lan, Li Zhang, Xiaoying Sun, Min Yang, Fei Ma
Summary: This study found an association between depression status and chemotherapy-induced myelosuppression in Chinese breast cancer patients receiving adjuvant chemotherapy, but no association with other adverse events.
Article
Oncology
Di Zhang, Lixi Li, Fei Ma
Summary: This study aimed to evaluate the impact of postoperative radiation therapy (RT) on survival outcome in patients with adenoid cystic carcinoma of the breast (ACCB). The study found that postoperative RT significantly improved overall survival in the high-risk subgroup but had no significant effect in the low-risk subgroup.
Article
Oncology
Hongmei Zeng, Siqi Wu, Fei Ma, John S. Ji, Lingeng Lu, Xianhui Ran, Jin Shi, Daojuan Li, Lan An, Rongshou Zheng, Siwei Zhang, Wanqing Chen, Wenqiang Wei, Yutong He, Jie He
Summary: The stage at diagnosis and molecular subtypes are important factors for breast cancer treatment and prognosis. This study aimed to examine the disparities and factors associated with the stage at diagnosis among molecular subtypes in Chinese breast cancer patients. The findings showed that China had a higher proportion of non-early-stage breast cancer compared to the United States, highlighting the need for improved early diagnosis and health equity in China.
Article
Oncology
Jiaxuan Liu, Maiyue He, Kaiping Ou, Xin Wang, Yipeng Wang, Liqiang Qi, Yue Chai, Mingxia Jiang, Fei Ma, Yang Luo, Peng Yuan, Pin Zhang, Binghe Xu, Qiao Li
Summary: This prospective cohort study investigated the efficacy and safety of apatinib combined with dose-dense paclitaxel and carboplatin (Apa+ddTCb) compared to dose-dense paclitaxel plus carboplatin regimens alone (ddTCb) in neoadjuvant therapy for locally advanced triple-negative breast cancer (TNBC). The results showed that the Apa+ddTCb regimen significantly improved pathological complete response (pCR) rate and breast-conserving surgery (BCS) rate compared to the ddTCb regimen, but had a higher incidence of adverse events. Immunohistochemical analysis also demonstrated decreased expression levels of VEGF, EGFR, p-VEGFR2, and CK17 in the Apa+ddTCb group. Overall, the Apa+ddTCb regimen may be a promising strategy for neoadjuvant therapy in locally advanced TNBC.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Medicine, General & Internal
Yi-Qun Li, Fang-Zhou Sun, Chun-Xiao Li, Hong-Nan Mo, Yan-Tong Zhou, Dan Lv, Jing-Tong Zhai, Hai-Li Qian, Fei Ma
Summary: The down-regulation of RARRES2 is specifically associated with brain metastasis (BrM) of triple negative breast cancer (TNBC) and promotes BrM through lipid metabolic reprogramming. Mechanistically, reduced expression of RARRES2 results in altered levels of glycerophospholipid and triacylglycerols by regulating the PTEN-mTOR-SREBP1 signaling pathway. This study uncovers the essential role of RARRES2 in linking lipid metabolic reprogramming and the development of BrM, providing potential biomarkers or therapeutic targets for BCBrM.
MILITARY MEDICAL RESEARCH
(2023)
Letter
Biochemistry & Molecular Biology
Xiuwen Guan, Fei Ma, Qiao Li, Shanshan Chen, Ying Fan, Jiayu Wang, Yang Luo, Pin Zhang, Qing Li, Binghe Xu
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2023)
Article
Oncology
Mingxia Jiang, Bin Shao, Donggui Wan, Jiaxuan Liu, Maiyue He, Yue Chai, Die Sang, Jiayu Wang, Fei Ma, Ying Fan, Peng Yuan, Binghe Xu, Qiao Li
Summary: This study retrospectively analyzed the efficacy and safety of eribulin combined with antiangiogenic drugs in the treatment of HER2-negative metastatic breast cancer. The results showed that this treatment regimen had significant clinical activity and an acceptable safety profile in HER2-negative MBC patients.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Article
Oncology
Ying Fan, Tao Sun, Zhimin Shao, Qingyuan Zhang, Quchang Ouyang, Zhongsheng Tong, Shusen Wang, Yang Luo, Yuee Teng, Xiaojia Wang, Shu Wang, Qiang Liu, Jifeng Feng, Kunwei Shen, Yanqiu Song, Jiayu Wang, Fei Ma, Qing Li, Pin Zhang, Binghe Xu
Summary: The study compared the effectiveness of everolimus plus letrozole with letrozole alone in premenopausal women with HR-positive/ERBB2-negative advanced breast cancer. The results showed that combination therapy significantly prolonged progression-free survival compared to letrozole monotherapy, even after crossover.